Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
3 Nasdaq Stocks That Are Up 25% in 3 Months
09:53am, Friday, 23'rd Dec 2022
Should you jump on the bandwagon and buy these surging stocks?
1 Green Flag and 1 Red Flag for Biogen
06:30am, Friday, 23'rd Dec 2022
Biogen beat the bear market this year.
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
09:53am, Thursday, 22'nd Dec 2022
Eli LIlly is looking to make waves in an important therapeutic area.
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
09:04am, Sunday, 18'th Dec 2022
Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
06:45am, Sunday, 18'th Dec 2022
These stocks have climbed by double digits this year.
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
06:00am, Sunday, 18'th Dec 2022
Both stocks are heading for double-digit gains this year.
Is Biogen (BIIB) Stock Undervalued Right Now?
11:17am, Thursday, 08'th Dec 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
12:02pm, Wednesday, 07'th Dec 2022
Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.
Why 2023 Could Be a Big Year for Biogen
10:38am, Wednesday, 07'th Dec 2022
Investors will soon learn if the company's Alzheimer's treatment gets the green light.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
09:49pm, Tuesday, 06'th Dec 2022
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Biogen Inc. (BIIB) Biogen and Sage Zuranolone Webcast Transcript
11:40am, Tuesday, 06'th Dec 2022
Biogen Inc. (NASDAQ:BIIB ) Biogen and Sage Zuranolone Webcast December 6, 2022 8:00 AM ET Company Participants Helen Rubinstein – Director-Investor Relations-Sage Therapeutics Chris Benecchi – Chi
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
11:17am, Tuesday, 06'th Dec 2022
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
Can These 2 Stocks Crush the Market Again in 2023?
09:37am, Sunday, 04'th Dec 2022
Both are riding the wave of major clinical wins
Is Biogen Stock a Buy Now?
08:30am, Sunday, 04'th Dec 2022
Its revenue now has a plausible path to doubling, but risks remain high.
Biogen Inc. (BIIB) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript)
09:28pm, Thursday, 01'st Dec 2022
Biogen Inc. (NASDAQ:BIIB ) 5th Annual Evercore ISI HealthCONx Conference Call December 1, 2022 10:30 AM ET Company Participants Mike McDonnell - Chief Financial Officer Priya Singhal - Head of Global
